Dr. Phillip J. Koo spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Friday, November 14, 2014 on “Utility of NaF PET/CT and Other Diagnostic Radiopharmaceuticals in Prostate Cancer.”

 

Keywords: diagnostic radiopharmaceuticals, prostate cancer, NaF, PET/CT[/su_tab]

How to cite: Koo, Phillip J. “Utility of NaF PET/CT and Other Diagnostic Radiopharmaceuticals in Prostate Cancer” Grand Rounds in Urology. July 21, 2015. Accessed Jul 2020. https://grandroundsinurology.com/prostate-cancer-phillip-j-koo-diagnostic-radiopharmaceuticals/.

References

Buchegger F, Garibotto V, Zilli T, et al. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):68-78.
http://www.ncbi.nlm.nih.gov/pubmed/24104592

Castellucci P, Picchio M. 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S36-40.
http://www.ncbi.nlm.nih.gov/pubmed/23579864

Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006 Feb;47(2):287-97.
http://www.ncbi.nlm.nih.gov/pubmed/16455635

Goldstein J, Even-Sapir E, Ben-Haim S, et al. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure? Am J Clin Oncol. 2014 Nov 4.
http://www.ncbi.nlm.nih.gov/pubmed/25319322

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
http://www.ncbi.nlm.nih.gov/pubmed/10647931

Hillman BJ, Frank RA, Abraham BC. The Medical Imaging & Technology Alliance conference on research endpoints appropriate for Medicare Coverage of New PET Radiopharmaceuticals. J Nucl Med. 2013 Sep;54(9):1675-9.
http://www.ncbi.nlm.nih.gov/pubmed/23907756

Hillner BE, Siegel BA, Hanna L, et al. Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry. J Nucl Med. 2014 Jul;55(7):1054-61
http://www.ncbi.nlm.nih.gov/pubmed/24819422

Kelloff GJ, Choyke P, Coffey DS, et al. Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol. 2009 Jun;192(6):1455-70.
http://www.ncbi.nlm.nih.gov/pubmed/19457806

Merdan S, Womble PR, Miller DC, et al. Toward Better Use of Bone Scans Among Men With Early-stage Prostate Cancer. Urology. 2014 Oct;84(4):793-8.
http://www.ncbi.nlm.nih.gov/pubmed/25096341

Tateishi U, Morita S, Taguri M, et al. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 2010 Aug;24(7):523-31.
http://www.ncbi.nlm.nih.gov/pubmed/20559896

von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun. 2014 Mar;35(3):221-30.
http://www.ncbi.nlm.nih.gov/pubmed/24240194